What interventions can be used to increase libido in a female patient?

Interventions to Increase Female Libido

Psychosocial or psychosexual counseling should be offered as first-line therapy for women with low libido, with mindfulness-based cognitive behavioral therapy (CBT) showing the strongest evidence for improving desire, arousal, and orgasm while reducing sexual distress. 1, 2, 3

Algorithmic Approach to Treatment

Step 1: Initial Assessment and Counseling

• Initiate discussion about sexual health - This conversation is vital and must occur before any intervention can be implemented 1
• Assess for contributing factors:
  • Body image issues
  • Relationship/intimacy problems
  • Underlying depression or anxiety
  • Menopausal status (pre- vs. postmenopausal)
  • Cancer history or endocrine therapy use

Step 2: First-Line Non-Pharmacological Interventions

Psychosocial/Psychosexual Counseling (strongest evidence):

• Mindfulness-based interventions rank highest for reducing sexual distress 3
• PLISSIT model-based sexual counseling ranks highest for improving overall sexual function 3
• CBT significantly improves desire, arousal, and orgasm domains 2, 3
• Individual, couples-based, or group formats are all effective 1
• If partnered, couples-based interventions show superior efficacy compared to usual care 1

Adjunctive Physical Interventions:

• Pelvic floor physiotherapy may provide additional benefit when combined with counseling 1
• Regular sexual stimulation (including masturbation) likely improves sexual response 1

Step 3: Pharmacological Options (If Counseling Insufficient After 6 Months)

For Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD):

Flibanserin (FDA-approved):

• Improves total sexual function and desire 2, 4, 5
• Critical caveat: Not evaluated in women with cancer history or on endocrine therapy; risk/benefit ratio uncertain 1
• Requires daily dosing

Bremelanotide (FDA-approved):

• Improves desire AND arousal (broader effect than flibanserin) 2, 4, 5
• On-demand dosing option
• May be preferred if arousal is also problematic

For Postmenopausal Women:

Vaginal testosterone (off-label, most effective):

• Improves desire, lubrication, satisfaction, and reduces pain 6
• Shows improvements in arousal, orgasm, and satisfaction over time 6
• Use formulations that maintain physiologic premenopausal testosterone concentrations 7
• Measure baseline total testosterone before starting 7
• Monitor testosterone levels at 3-6 weeks, then every 6 months 7
• Discontinue if no benefit by 6 months 7

Vaginal estrogen:

• Improves desire domain 6
• Addresses vaginal atrophy contributing to dysfunction
• Less comprehensive effect than testosterone for libido specifically

Polyacrylic acid (vaginal lubricant):

• Improves desire, lubrication, satisfaction, and pain 6
• Non-hormonal option when hormones contraindicated

Step 4: Monitoring and Adjustment

For Psychotherapy:

• Assess response at 3 and 6 months 8
• Key mediators of success include improvements in self-compassion, reduced rumination, enhanced body connection, and decreased self-consciousness 8

For Pharmacotherapy:

• Baseline assessment before starting
• Reassess at 6 months
• Discontinue if no benefit by 6 months 7
• Monitor for androgen excess with testosterone therapy 7

Critical Caveats and Pitfalls

Avoid These Common Errors:

1. Never use testosterone preparations causing supraphysiologic levels (pellets, injections) 7
2. Compounded "bioidentical" testosterone cannot be recommended due to lack of efficacy/safety data 7
3. Do not use systemic DHEA - not effective for libido in women with normal adrenal function 7
4. Flibanserin and bremelanotide have uncertain safety in cancer patients or those on endocrine therapy 1

Special Populations:

Women with Cancer:

• Psychosocial counseling remains primary recommendation 1
• Screen for body image issues early and repeatedly 1
• Address vasomotor symptoms if present (may use hormone therapy if non-hormone-sensitive cancer) 1

Postmenopausal Women:

• Prioritize vaginal testosterone over systemic options for libido 6
• Consider local estrogen if vaginal atrophy is primary concern 6

Evidence Quality Considerations

The 2018 ASCO guidelines [1-1 provide the strongest framework but are specific to cancer populations. The 2019 Global Consensus on testosterone 7 provides definitive guidance on androgen therapy. The most recent 2026 meta-analyses 2, 3 demonstrate that mindfulness-based CBT ranks highest for distress reduction while PLISSIT model ranks highest for functional improvement, though both CBT and mindfulness show significant benefits across all domains. The comparative effectiveness between psychological and pharmacological approaches has not been directly studied, but psychological interventions show broader improvements across multiple domains of sexual function 2, 3.